Tokyo, Aug 3, 2011 (JCN) - Takara Bio and Tianjin Medical University, Cancer Institute and Hospital (TMUCIH) have agreed to a collaboration, working together in clinical research of TCR gene therapy against refractory cancer. Both parties wish to start clinical research within two years.
The lymphocytes from patients will be transduced in vitro with the retrovirus vector having the TCR gene, which specifically recognizes the tumor cells. The gene modified lymphocytes will be grown in vitro culture, and then they will be re-infused into patients. These lymphocytes are expected to specifically recognize and attack tumors in the patients.
Although Takara is now doing several clinical development projects concerning cancer and AIDS in Japan as well as in the U.S., this is the first gene therapy project in China. Takara is starting up this TCR gene therapy project, and it plans to further expand its business in the field of the cell and gene therapy.
Takara and Mie University, School of Medicine are now jointly conducting clinical research on TCR gene therapy against refractory esophageal cancer. Takara plans to start the clinical trial in Japan with regard to TCR gene therapy in the fiscal year of 2013. Dr. Steven A. Rosenberg and his colleagues in the U.S. NCI published the results of their clinical trial of TCR gene therapy for melanoma patients in the journal Science in 2006, which reported promising results for this therapy. They employ RetroNectin in the clinical trial, which was developed by Takara. Since that time, several groups including Dr. Rosenberg's group have performed clinical trials showing the efficacy of TCR gene therapy for several kinds of cancers in addition to melanoma.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial
(Jan 7, 2013)
|
|
|
Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA
(Mar 23, 2012)
|
|
|
Takara Bio and Tianjin Medical University in Gene Therapy Project
(Aug 3, 2011)
|
|
|
Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma
(Dec 18, 2008)
|
|
|
Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China
(May 2, 2008)
|
|
|
Takara Bio Grants Transgenomic License for LA-PCR Technology
(May 7, 2007)
|
|
|
ViroMed Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis
(Jan 11, 2007)
|
|
|
Takara Bio's RetroNect Used in Australia for Gene Therapy Clinical Trials of Multiple Myeloma
(Dec 18, 2006)
|
|
|
Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia
(Sept 7, 2006)
|
|
|
Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia
(Sept 7, 2006)
|
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Biotech news...
|
|
